Pacer Advisors
COGT icon

Pacer Advisors’s Cogent Biosciences COGT Stock Holding History

Pacer Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,046
Closed -$8.82K – 2590
2024
Q2 		$8.82K Sell
1,046
-2,233
-68% -$16.9K ﹤0.01% 3568
2024
Q1 		$22K Buy
+3,279
New +$20.3K ﹤0.01% 3427

Other funds holding COGT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Pacer Advisors's COGT Position: Q3 2024 in Review

Pacer Advisors sold out of Cogent Biosciences (COGT) in Q3 2024, closing a stake of 1,046 shares — an estimated $8.82K sold.

Pacer Advisors first reported a position in COGT in Q1 2024 and held it in 2 quarters. The position peaked at $22K in Q1 2024. 161 funds tracked by Wall St. Rank hold COGT as of Q3 2024.

  • Pacer Advisors reported no remaining Cogent Biosciences position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,046 Cogent Biosciences shares in Q3 2024, an estimated $8.82K.
  • Pacer Advisors first reported a position in Cogent Biosciences in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Cogent Biosciences position peaked at $22K in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.